Annovis Bio Files 8-K, Updates Corporate Info
Ticker: ANVS · Form: 8-K · Filed: Jul 16, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, company-information
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) filed an 8-K on 7/16, updating corporate details and former name.
AI Summary
Annovis Bio, Inc. filed an 8-K on July 16, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355, and its principal executive office phone number is 484-875-3192. The company was formerly known as QR Pharma, Inc., with a name change effective December 2, 2009.
Why It Matters
This filing provides essential corporate information and updates for Annovis Bio, Inc., which is relevant for investors tracking the company's official disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former Company Name
- July 16, 2024 (date) — Date of Report
- 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 (address) — Principal Executive Offices
- 484-875-3192 (phone_number) — Registrant's Telephone Number
- December 2, 2009 (date) — Date of Name Change
FAQ
What is the exact name of the registrant?
The exact name of the registrant is Annovis Bio, Inc.
On what date was this 8-K report filed?
The report was filed on July 16, 2024.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
When was the name change from QR Pharma, Inc. to Annovis Bio, Inc. effective?
The name change was effective on December 2, 2009.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-07-16 08:05:57
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2419484d1_8k.htm (8-K) — 26KB
- tm2419484d1_ex99-1.htm (EX-99.1) — 8KB
- 0001104659-24-080039.txt ( ) — 208KB
- anvs-20240716.xsd (EX-101.SCH) — 3KB
- anvs-20240716_lab.xml (EX-101.LAB) — 33KB
- anvs-20240716_pre.xml (EX-101.PRE) — 22KB
- tm2419484d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 16, 2024, Annovis Bio, Inc. ("The Company") issued a press release announcing FDA approval to transition to its new crystal form of Buntanetap for future clinical trials. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated July 16, 2024 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: July 16, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer